Metoprolol — Membership Pricing

Related medications

Other medications associated with the same conditions in this catalog.

Also listed for Atrial Fibrillation (Stroke Prevention)

• Warfarin Sodium
• Amiodarone
• Apixaban
• Dabigatran
• Digoxin
• Rivaroxaban
• Warfarin

Also listed for Coronary Artery Disease

• Aspirin

Other medications in Heart & Cardiovascular

• Milrinone
• Moexipril
• Nadolol
• Nebivolol
• Nesiritide
• Nicardipine
• Nifedipine
• Nisoldipine

About Metoprolol

Metoprolol is a widely prescribed medication crucial for managing various heart conditions. For many, its daily use is essential for maintaining well-being. At TheDrugClub, we believe access to vital medications like metoprolol shouldn't be a financial burden. Discover how our membership can make a significant difference in your healthcare costs.

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Metoprolol is approved for (FDA label)

Metoprolol tartrate tablet is a beta-adrenergic blocker indicated for the treatment of: • Hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.1 ) • Angina Pectoris. ( 1.2 ) • Myocardial Infarction, to reduce the risk of cardiovascular mortality when used in conjunction with intravenous metoprolol therapy in patients with definite or suspected acute myocardial infarction in hemodynamically stable patients. ( 1.3 ) 1.1 Hypertension Metoprolol tartrate tablets are indicated for the treatment of hypertension in adult patients, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions.

Source: Read the full FDA label on DailyMed. Label effective date: August 26, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Metoprolol (FDA label)

Metoprolol tartrate tablets, USP are supplied as: 25 mg tablets having functional scoring are white to off white film coated, round, biconvex tablet debossed with ‘L150’ on one side and breakline on other side. 50 mg tablets having functional scoring are pink, film coated, round, biconvex tablet debossed with ‘L151’ on one side and breakline on other side. 100 mg tablets having functional scoring are blue, film coated, round, biconvex tablet debossed with ‘L152’ on one side and breakline on other side. • Metoprolol tartrate tablets having functional scoring: 25 mg, 50 mg and 100 mg. ( 3 )

Source: FDA prescribing information (DailyMed). Set ID: 59ed27b8-32b5-60c0-e063-6394a90a8a23. SPL document ID: 59ed27b8-32b6-60c0-e063-6394a90a8a23. Label effective date: August 26, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Metoprolol (FDA label)

The following adverse reactions are described elsewhere in labeling: Worsening angina or myocardial infarction [see Warnings and Precautions (5)] Worsening heart failure [see Warnings and Precautions (5)]. Worsening AV block [see Contraindications (4)]. • Most common adverse reactions: tiredness, dizziness, depression, shortness of breath, bradycardia, hypotension, diarrhea, pruritus, rash. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Alembic Pharmaceuticals Limited at 1-866-210-9797 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Source: FDA prescribing information (DailyMed). Set ID: 59ed27b8-32b5-60c0-e063-6394a90a8a23. SPL document ID: 59ed27b8-32b6-60c0-e063-6394a90a8a23. Label effective date: August 26, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Metoprolol (FDA label)

Metoprolol tartrate tablets are contraindicated in severe bradycardia, second-or third-degree heart block, cardiogenic shock, systolic blood pressure <100, decompensated heart failure, sick sinus syndrome (unless a permanent pacemaker is in place), and in patients who are hypersensitive to any component of this product. • Known hypersensitivity to product components. ( 4 ) • Severe bradycardia: Greater than first degree heart block, or sick sinus syndrome without a pacemaker. ( 4 ) • Cardiogenic shock or decompensated heart failure. ( 4 )

Source: FDA prescribing information (DailyMed). Set ID: 59ed27b8-32b5-60c0-e063-6394a90a8a23. SPL document ID: 59ed27b8-32b6-60c0-e063-6394a90a8a23. Label effective date: August 26, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Metoprolol (FDA label)

• Abrupt cessation may exacerbate myocardial ischemia. ( 5.1 ) • Heart Failure: Worsening cardiac failure may occur. ( 5.2 ) • Bronchospastic Disease: Avoid beta-blockers. ( 5.3 ) • Pheochromocytoma: Initiate therapy with an alpha blocker. ( 5.4 ) • Major Surgery: Avoid initiation of high-dose extended-release metoprolol in patients undergoing non-cardiac surgery. Do not routinely withdraw chronic beta-blocker therapy prior to surgery. ( 5.5 , 6.1 ) • Diabetes: May mask symptoms of hypoglycemia. ( 5.6 ) • Thyrotoxicosis: Abrupt withdrawal in patients with thyrotoxicosis might precipitate a thyroid storm. ( 5.7 ) • Peripheral Vascular Disease: Can aggravate symptoms of arterial insufficiency. ( 5.9 ) 5.1 Abrupt Cessation of Therapy Following abrupt cessation of therapy with certain beta-blocking agents, exacerbations of angina pectoris and, in some cases, myocardial infarction have occurred.

Source: FDA prescribing information (DailyMed). Set ID: 59ed27b8-32b5-60c0-e063-6394a90a8a23. SPL document ID: 59ed27b8-32b6-60c0-e063-6394a90a8a23. Label effective date: August 26, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Metoprolol (FDA label)

• Catecholamine-depleting drugs may have an additive effect when given with beta-blocking agents. ( 7.1 ) • Patients may be unresponsive to the usual doses of epinephrine used to treat allergic reaction. ( 7.2 ) • CYP2D6 Inhibitors are likely to increase metoprolol concentration. ( 7.3 ) • Concomitant use of glycosides, clonidine, and diltiazem and verapamil with beta-blockers can increase the risk of bradycardia. ( 7.4 ) • Beta-blockers including metoprolol, may exacerbate the rebound hypertension that can follow the withdrawal of clonidine. ( 7.4 ) 7.1 Catecholamine Depleting Drugs Catecholamine depleting drugs (e.g., reserpine, monoamine oxidase (MAO) inhibitors) may have an additive effect when given with beta-blocking agents.

Source: FDA prescribing information (DailyMed). Set ID: 59ed27b8-32b5-60c0-e063-6394a90a8a23. SPL document ID: 59ed27b8-32b6-60c0-e063-6394a90a8a23. Label effective date: August 26, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.